On October 18, 2021 Evopoint Biosciences reported XNW7201 approved by Beijing Cancer Hospital, the unit of the team leader, for the Phase IIa clinical trial on October 18, 2021 (Press release, Evopoint Biosciences, OCT 18, 2021, View Source [SID1234656283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Variation of Wnt signaling pathway is common in gastrointestinal tumors (e.g., gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc.). Inhibition of Porcupine protein can block the abnormally activated Wnt signaling pathway. Moreover, it has been confirmed that the use of Wnt inhibitor is expected to enhance the effect of tumor immunotherapy. In this regard, Evopoint will continue to make every effort to promote the Phase IIa clinical trial of XNW7201 and strive to accelerate product launch for the benefit of numerous sufferers.